These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

778 related articles for article (PubMed ID: 23647644)

  • 1. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
    Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S
    Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
    Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: analysis of 10-year Japanese postmarketing surveillance data.
    Amano K; Seita I; Higasa S; Sawada A; Kuwahara M; Shima M
    Haemophilia; 2017 Jan; 23(1):50-58. PubMed ID: 27457022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg⁻¹) rFVIIa doses across clinical trials and registries.
    Shapiro AD; Neufeld EJ; Blanchette V; Salaj P; Gut RZ; Cooper DL
    Haemophilia; 2014 Jan; 20(1):e23-31. PubMed ID: 24354484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
    Parameswaran R; Shapiro AD; Gill JC; Kessler CM;
    Haemophilia; 2005 Mar; 11(2):100-6. PubMed ID: 15810910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of individual dose utilization vs. physician prescribing recommendations for recombinant activated factor VII (rFVIIa) in paediatric and adult patients with congenital haemophilia and alloantibody inhibitors (CHwI): the Dosing Observational Study in Hemophilia (DOSE).
    Gruppo RA; Kessler CM; Neufeld EJ; Cooper DL
    Haemophilia; 2013 Jul; 19(4):524-32. PubMed ID: 23551918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elective surgery in patients with congenital coagulopathies and inhibitors: experience of the National Haemophilia Centre of Venezuela.
    Boadas A; Fernández-Palazzi F; De Bosch NB; Cedeño M; Ruiz-Sáez A
    Haemophilia; 2011 May; 17(3):422-7. PubMed ID: 21118333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008).
    Neufeld EJ; Kessler CM; Gill JC; Wilke CT; Cooper DL;
    Haemophilia; 2011 Jul; 17(4):650-6. PubMed ID: 21299750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors.
    Santagostino E; Escobar M; Ozelo M; Solimeno L; Arkhammar P; Lee HY; Rosu G; Giangrande P
    Blood Rev; 2015 Jun; 29 Suppl 1():S9-18. PubMed ID: 26073369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eptacog alfa activated: a recombinant product to treat rare congenital bleeding disorders.
    Di Minno G
    Blood Rev; 2015 Jun; 29 Suppl 1():S26-33. PubMed ID: 26073366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors.
    Qi X; Zhao Y; Li K; Fan L; Hua B
    Blood Coagul Fibrinolysis; 2014 Oct; 25(7):754-60. PubMed ID: 24806320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten-year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan.
    Takedani H; Shima M; Horikoshi Y; Koyama T; Fukutake K; Kuwahara M; Ishiguro N
    Haemophilia; 2015 May; 21(3):374-379. PubMed ID: 25521821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant activated factor VII: 30 years of research and innovation.
    Hedner U
    Blood Rev; 2015 Jun; 29 Suppl 1():S4-8. PubMed ID: 26073368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant activated factor VII as a universal haemostatic agent.
    Hedner U
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S147-52. PubMed ID: 9819047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of recombinant activated factor VII in patients with acquired haemophilia.
    Tiede A; Amano K; Ma A; Arkhammar P; El Fegoun SB; Rosholm A; Seremetis S; Baudo F
    Blood Rev; 2015 Jun; 29 Suppl 1():S19-25. PubMed ID: 26073365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven®, in the treatment of haemophilia and rare bleeding disorders.
    Shima M
    Ann Hematol; 2024 Aug; 103(8):2647-2658. PubMed ID: 37391649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
    Scharrer I
    Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)?
    Brackmann HH; Effenberger W; Hess L; Schwaab R; Oldenburg J
    Eur J Haematol Suppl; 1998; 63():18-23. PubMed ID: 9882928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of FVIII and low-dose rFVIIa improves haemostasis in acquired haemophilia A patients: a collaborative controlled study.
    Zhang XH; Zhu XL; Niu T; Sun J; Liu H; Feng R; Yang LH; Wei Q; Ma QH; Wang QM; Feng FE; Fu HX; Mo XD; Lv M; Huang XJ
    Thromb Res; 2015 May; 135(5):835-40. PubMed ID: 25747536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. To general haemostasis--the evidence-based route.
    Erhardtsen E
    Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():47-52. PubMed ID: 12214148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.